NCCN Breast Cancer Guidelines

New NCCN Breast Cancer Guidelines recognize Oncotype DX Breast Recurrence Score® as the “preferred” and only multigene test to predict chemotherapy benefit in node-positive early-stage breast cancer

Landmark RxPONDER Trial Results

Presented at the 2020 SABCS

Learn more about the data from the RxPONDER trial and how it successfully defines the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Oncotype DX Breast Recurrence Score® results of 0 to 25.

Le site OncotypeIQ.com Canada est aussi disponible en français

Si vous souhaitez visiter notre site OncotypeIQ.com Canada en français, suivez ce lien
Making cancer care smarter.®
X

This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By continuing to use this website, you agree that we can place these types of cookies on your device. For more information, please read our privacy policy.